Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

Selective BRAF inhibitors such as vemurafenib have become a treatment option in patients with Langerhans cell Histiocytosis (LCH). To date, only 14 patients receiving vemurafenib for LCH have been reported. Although vemurafenib can stabilize the clinical condition of these patients, it does not seem...

Descripción completa

Detalles Bibliográficos
Autores principales: Heisig, Anne, Sörensen, Jan, Zimmermann, Stefanie-Yvonne, Schöning, Stefan, Schwabe, Dirk, Kvasnicka, Hans-Michael, Schwentner, Raphaela, Hutter, Caroline, Lehrnbecher, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://www.ncbi.nlm.nih.gov/pubmed/29774135
http://dx.doi.org/10.18632/oncotarget.25277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955145/
https://www.ncbi.nlm.nih.gov/pubmed/29774135
http://dx.doi.org/10.18632/oncotarget.25277

Ejemplares similares